H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND) today and set a price target of $237.00. The company’s shares closed last Monday at $76.92.
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -7.7% and a 27.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Ligand Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $171.50.
See today’s analyst top recommended stocks >>
Ligand Pharma’s market cap is currently $1.21B and has a P/E ratio of 2.40. The company has a Price to Book ratio of 2.74.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LGND in relation to earlier this year. Last month, Matthew W. Foehr, the President & COO of LGND bought 2,000 shares for a total of $43,840.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
